Cita APA

van den Bemt, B. J., den Broeder, A. A., Wolbink, G., Hekster, Y. A., van Riel, P. L., Benraad, B., & van den Hoogen, F. H. (2011). Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: An open-label pharmacokinetic cohort study. BioMed Central.

Citación estilo Chicago

van den Bemt, Bart JF, Alfons A. den Broeder, GJ Wolbink, Yechiel A. Hekster, Piet LCM van Riel, Bart Benraad, y Frank HJ van den Hoogen. Anti-infliximab Antibodies Are Already Detectable in Most Patients With Rheumatoid Arthritis Halfway Through an Infusioncycle: An Open-label Pharmacokinetic Cohort Study. BioMed Central, 2011.

Cita MLA

van den Bemt, Bart JF, et al. Anti-infliximab Antibodies Are Already Detectable in Most Patients With Rheumatoid Arthritis Halfway Through an Infusioncycle: An Open-label Pharmacokinetic Cohort Study. BioMed Central, 2011.